Our global biomarker services facilitate the translation of biomarkers from discovery to the clinic, covering safety assessment across therapeutic areas. Using genomics, transcriptomics, proteomics, flow cytometry, and metabolomics, we offer diverse approaches to discover and develop biologically relevant biomarkers. Our experts collaborate across multiple areas, ensuring scientific excellence from assay qualification to fit-for-purpose validations, contributing to confident decision-making in drug development.

Identification of Predictive Biomarkers

The integration of predictive biomarker assays into the drug discovery and development process has become essential. Charles River possesses extensive expertise in identifying and developing biomarkers across various therapeutic areas, encompassing respiratory disease, oncology, CNS, and metabolic diseases.

Biomarker Analysis Services

Biomarker assays and analytical readouts are important tools in drug discovery from target validation studies to candidate selection, so the ability to measure with accuracy and sensitivity is essential in making critical go/no-go study decisions. With years of experience in assay design and sample processing, Charles River can support your drug discovery pipeline by providing biomarker analysis services in a non-GxP environment. Whether your study is performed at your facility or designed and implemented at ours, our focus on strategic assay validation/qualification enables us to accurately test your study samples and provide reliable biological translation to your drug discovery program.